Annexon reports Q4 and FY2025 net loss of $48.3M and $208.5M; cash $238.3M; vonaprument Phase 3 data due Q4 2026

Annexon, Inc.

Net loss Q4 2025 $48.3M ($0.28/sh) and FY2025 $208.5M ($1.34/sh); FY2024 net loss was $138.2M.
Cash, equivalents and short-term investments $238.3M at Dec 31, 2025; funds operations into H2 2027.
R&D expenses $184.7M for FY2025, up from $119.4M due to Phase 3 ARCHER II and regulatory filings.
Vonaprument Phase 3 ARCHER II topline data in geographic atrophy expected Q4 2026; enrollment completed July 2025.
Tanruprubart MAA filed in EU for GBS; U.S. BLA submission planned in 2026 based on FORWARD study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Annexon, Inc. reported financial results for the fourth quarter and the year ended December 31, 2025.

Period: the fourth quarter and the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 30, 2026, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-131746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.